Detalhe da pesquisa
1.
Genome-wide association study identifies novel susceptibility loci for KIT D816V positive mastocytosis.
Am J Hum Genet
; 108(2): 284-294, 2021 02 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33421400
2.
Response and resistance to cladribine in patients with advanced systemic mastocytosis: a registry-based analysis.
Ann Hematol
; 102(8): 2077-2085, 2023 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-37012462
3.
The ABNL-MARRO 001 study: a phase 1-2 study of randomly allocated active myeloid target compound combinations in MDS/MPN overlap syndromes.
BMC Cancer
; 22(1): 1013, 2022 Sep 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-36153475
4.
Chronic Eosinophilic Leukaemia Associated with JAK2 Exon 13 Insertion/Deletion Mutations.
Acta Haematol
; 145(2): 201-206, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-34515041
5.
Clinical and histopathological features of myeloid neoplasms with concurrent Janus kinase 2 (JAK2) V617F and KIT proto-oncogene, receptor tyrosine kinase (KIT) D816V mutations.
Br J Haematol
; 194(2): 344-354, 2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-34060083
6.
Real-world tyrosine kinase inhibitor treatment pathways, monitoring patterns and responses in patients with chronic myeloid leukaemia in the United Kingdom: the UK TARGET CML study.
Br J Haematol
; 192(1): 62-74, 2021 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32449159
7.
JAK2 ex13InDel drives oncogenic transformation and is associated with chronic eosinophilic leukemia and polycythemia vera.
Blood
; 134(26): 2388-2398, 2019 12 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-31697804
8.
Adverse Prognostic Impact of the KIT D816V Transcriptional Activity in Advanced Systemic Mastocytosis.
Int J Mol Sci
; 22(5)2021 Mar 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33806359
9.
Response to tyrosine kinase inhibitors in myeloid neoplasms associated with PCM1-JAK2, BCR-JAK2 and ETV6-ABL1 fusion genes.
Am J Hematol
; 95(7): 824-833, 2020 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-32279331
10.
The management of myelofibrosis: A British Society for Haematology Guideline.
Br J Haematol
; 204(1): 136-150, 2024 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38037886
11.
Diagnosis and evaluation of prognosis of myelofibrosis: A British Society for Haematology Guideline.
Br J Haematol
; 204(1): 127-135, 2024 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37932932
12.
Response and progression on midostaurin in advanced systemic mastocytosis: KIT D816V and other molecular markers.
Blood
; 130(2): 137-145, 2017 07 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-28424161
13.
Ruxolitinib vs best available therapy for ET intolerant or resistant to hydroxycarbamide.
Blood
; 130(17): 1889-1897, 2017 10 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-29074595
14.
A Novel t(1;9)(p36;p24.1) JAK2 Translocation and Review of the Literature.
Acta Haematol
; 142(2): 105-112, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-31063994
15.
Incidence and prognostic impact of cytogenetic aberrations in patients with systemic mastocytosis.
Genes Chromosomes Cancer
; 57(5): 252-259, 2018 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-29341334
16.
Consensus on BCR-ABL1 reporting in chronic myeloid leukaemia in the UK.
Br J Haematol
; 182(6): 777-788, 2018 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-30125955
17.
The effect of initial molecular profile on response to recombinant interferon-α (rIFNα) treatment in early myelofibrosis.
Cancer
; 123(14): 2680-2687, 2017 Jul 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-28518222
18.
Measurement of BCR-ABL1 by RT-qPCR in chronic myeloid leukaemia: findings from an International EQA Programme.
Br J Haematol
; 177(3): 414-422, 2017 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-28295199
19.
An international consortium proposal of uniform response criteria for myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in adults.
Blood
; 125(12): 1857-65, 2015 Mar 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-25624319
20.
The clinical and molecular diversity of mast cell leukemia with or without associated hematologic neoplasm.
Haematologica
; 102(6): 1035-1043, 2017 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-28255023